Lung Cancer Market Size, Share, Growth, and Industry Analysis, By Type (Surgery,Chemotherapy,Radiotherapy,Photodynamic therapy (PDT),Laser therapyS), By Application (Hospitals & Clinics,Cancer Research Centers,Laboratories), Regional Insights and Forecast to 2035

Lung Cancer Market Overview

Global Lung Cancer Market valued at USD 38954.17 Million in 2026, projected to reach USD 102675.75 Million by 2035, growing at a CAGR of 11.37%.

The lung cancer market analysis shows that over 2.2 million new lung cancer cases were reported globally in 2024, with 1.8 million related deaths across 100+ countries. According to market research reports, lung cancer accounted for 11% of all cancer cases worldwide in 2024, highlighting the market size and market share potential of advanced diagnostic and treatment options.

In 2024, targeted therapies represented 42% of new treatment approaches while 36% came from immunotherapy developments, significantly impacting industry analysis and market trends. By 2033, research predicts 5.6 million patients will receive targeted therapy-based treatment worldwide. The market report indicates increasing government funding, with more than 50 global oncology research programs initiated in 2024, showing the market opportunities and market growth in lung cancer treatment.

The market outlook reveals that AI-assisted early detection techniques are being integrated in 60% of major hospitals globally by 2027. The future market insights for lung cancer treatment highlight expansion in screening programs, genetic profiling, and B2B collaborations between pharmaceutical companies and healthcare facilities to improve diagnosis accuracy by 45% within the next decade.

In the USA lung cancer market, 236,000 new cases were reported in 2024, accounting for 13% of all cancers in the country. Approximately 130,000 deaths occurred due to lung cancer in 2024, making it the leading cause of cancer-related mortality. The market report shows that 59% of new treatments involved immunotherapies, with 41% targeted therapy. In 2024, more than 520 hospitals adopted AI-based early detection tools, improving diagnosis accuracy by 37%. Around 45% of clinical trials for lung cancer drugs globally are conducted in the USA. Market insights reveal that more than 65% of B2B investments in the oncology sector in the USA are allocated to lung cancer treatment innovations, which strongly influences the market size, market trends, and market growth projections.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 68% rising cases globally, 59% new drug adoption, 63% AI-based diagnostic improvements, 48% rising demand for targeted therapies, 54% hospital partnerships.
• Major Market Restraint: 52% limited access in low-income regions, 46% cost burden, 49% shortage of trained professionals, 41% drug side-effect cases, 44% slow regulatory approvals.
• Emerging Trends: 66% precision medicine growth, 58% immunotherapy adoption, 72% AI integration in screening, 61% biomarker-driven research, 64% B2B clinical collaborations.
• Regional Leadership: 34% USA share, 27% Europe, 28% Asia-Pacific, 6% Middle East, 5% Africa with 49% cross-border drug trials.
• Competitive Landscape: 53% dominated by top 15 companies, 45% innovation in targeted therapy, 66% collaborations with research centers, 42% patents filed for new molecules, 47% rise in drug pipeline.
• Market Segmentation: 62% drug treatments, 38% surgical interventions, 56% hospital-based care, 44% research centers, 41% personalized medicine.
• Recent Development: 63% AI trials launched, 55% hospital collaborations, 58% funding growth in oncology, 61% new immunotherapy programs, 49% digital diagnostic platforms launched.

Lung Cancer Market Trends

The lung cancer market trends indicate that advancements in immunotherapy, early detection systems, and biomarker-driven treatment approaches are reshaping the global market outlook. Market research reports confirm that over 2.2 million lung cancer cases in 2024 drive continuous innovation in diagnostics and therapy. In 2024, more than 700 active clinical trials were ongoing worldwide, with 290 conducted in the USA alone. Precision medicine accounted for 66% of new research studies. Industry analysis shows AI-driven imaging technologies improved early detection by 43%, particularly in hospitals in North America and Europe. The market forecast projects that by 2030, more than 70% of lung cancer patients globally will be diagnosed at an earlier stage compared to 45% in 2024. B2B partnerships have expanded, with 410 new collaborations between pharmaceutical companies and healthcare facilities signed in 2024, showing a 38% rise over the previous year. Market size is also driven by rising awareness campaigns as 62% of urban populations undergo annual screenings. The industry report highlights that immune checkpoint inhibitors contributed to 59% of therapeutic success rates, and molecular diagnostics are projected to grow rapidly over the next decade, generating market opportunities across research, pharmaceutical innovation, and healthcare delivery.

Lung Cancer Market Dynamics

The lung cancer market dynamics reflect a complex mix of drivers, restraints, opportunities, and challenges. Rising incidence of 2.2 million new cases in 2024 drives demand for advanced treatment solutions, while increasing adoption of precision medicine and AI-based screening technologies strengthens the market size and market share. However, market analysis highlights that cost-intensive therapies limit access for 52% of patients in low- and middle-income countries. Despite these issues, 66% of pharmaceutical companies expanded their drug development programs in 2024. Market research reports indicate that collaborations between healthcare institutions and technology companies have increased by 41%, improving the industry outlook. These trends are shaping the global market growth, with more than 500 oncology-focused companies involved in the pipeline of new lung cancer drugs.

DRIVER

"Increasing global incidence of lung cancer is a major market driver."

With 2.2 million new cases of lung cancer reported globally in 2024, there is significant pressure on healthcare systems to provide advanced diagnostics and therapies. Lung cancer accounted for 11% of global cancer cases and 18% of cancer-related deaths in 2024. This surge has resulted in more than 480 new drug trials being initiated worldwide in the same year. Market analysis shows that the number of AI-driven early detection systems increased by 43% in hospitals worldwide, particularly in the USA and Europe. These developments underline the increasing market opportunities and market growth potential for the lung cancer market.

RESTRAINT

"High treatment costs and slow access create barriers to patient care."

The high cost of immunotherapy and targeted therapy, which can range up to USD 150,000 per patient per year, restricts access for 52% of lung cancer patients globally. According to industry reports, 46% of hospitals in low-income countries lack the infrastructure to provide advanced treatment. Additionally, 41% of patients discontinue treatment due to side effects, and 44% of new drugs face delays in regulatory approval, which hampers the market size and market share expansion.

OPPORTUNITY

"Advancements in AI and precision medicine create growth opportunities."

The market report shows that 66% of new clinical studies are focused on precision medicine, enabling doctors to create personalized therapies. AI-assisted diagnostics reduced late-stage detection cases by 38% in 2024 compared to 2020. More than 320 global collaborations were signed in 2024 between pharmaceutical firms and healthcare systems for early diagnosis technologies. Industry analysis confirms that early detection and targeted therapies can improve 5-year survival rates by 41%, which is a major factor driving market growth.

CHALLENGE

"Shortage of skilled professionals and slow infrastructure growth hinder progress."

According to market research reports, there is a shortage of 36% in oncology specialists worldwide, which slows the adoption of advanced treatment techniques. Approximately 49% of low- and middle-income regions lack adequate research centers. Even in high-income countries, 42% of healthcare facilities struggle with integrating AI diagnostic tools. This shortage presents a major challenge to improving market share and treatment outcomes.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

Lung Cancer Market Segmentation

Market research reports reveal that the lung cancer market is segmented by type and application. By 2024, drug treatments such as chemotherapy and immunotherapy represented 62% of treatment approaches, while surgical interventions accounted for 38%. Applications were divided between hospitals and clinics, which represented 56% of the market, and cancer research centers, which accounted for 44%.

BY TYPE

Surgery: Surgery remains a primary treatment for 25% of lung cancer cases detected in early stages. In 2024, approximately 450,000 surgeries were performed worldwide. According to industry analysis, 38% of these procedures took place in North America, 30% in Europe, and 25% in Asia-Pacific. Technological advances like robotic-assisted surgery improved surgical success rates by 29%.

The lung cancer surgery segment is valued at USD 14.2 billion in 2024, accounting for 46 percent of the global market share and projected to grow at a CAGR of 6.1 percent from 2024 to 2030, driven by increasing adoption of minimally invasive surgical techniques.

Top 5 Major Dominant Countries in the Surgery Segment

• United States: The United States lung cancer surgery market stands at USD 5.2 billion, 37 percent share and 6.0 percent CAGR, driven by advanced robotic-assisted surgical techniques, leading oncology centers, and early-stage patient screening programs aimed at improving post-surgical recovery and survival outcomes across diverse demographics.
• China: China’s lung cancer surgery market is valued at USD 2.1 billion, 15 percent share and 6.4 percent CAGR, propelled by a large patient pool, increasing investment in hospital infrastructure, and improvements in diagnostic methods leading to a higher volume of operable cancer cases.
• Germany: Germany’s market size in surgery is USD 1.4 billion, 10 percent share with a 6.0 percent CAGR, driven by innovative thoracic surgery procedures, expansion of cancer treatment facilities, and adoption of minimally invasive techniques for early-stage lung cancer patients.
• Japan: Japan records USD 1.3 billion, 9 percent share and 6.1 percent CAGR, with growth supported by an aging population, highly specialized surgeons, and early lung cancer screening programs combined with improved public awareness of surgical treatment options.
• India: India’s lung cancer surgery market stands at USD 1.0 billion, 7 percent share and 6.5 percent CAGR, driven by expanding hospital infrastructure, improved access to diagnostic technologies, and the increasing demand for cost-effective surgical interventions for lung cancer patients.

Chemotherapy: Chemotherapy continues to be a major treatment approach, with 1.3 million patients undergoing chemotherapy for lung cancer in 2024. Industry reports indicate that 61% of patients receive chemotherapy as a combination therapy with immunotherapy. Hospitals worldwide have reported a 34% increase in chemotherapy effectiveness when combined with biomarker analysis for personalized treatment plans.

The chemotherapy segment of the lung cancer market has a market value of USD 16.8 billion in 2024, representing 54 percent share and is expected to grow at a CAGR of 5.8 percent during 2024–2030 due to growing usage of targeted drugs and combination therapies.

Top 5 Major Dominant Countries in the Chemotherapy Segment

• United States: The United States chemotherapy market for lung cancer totals USD 6.5 billion, 39 percent share and 5.7 percent CAGR, driven by access to advanced treatment protocols, rapid uptake of immunotherapy-drug combinations, and a strong oncology drug development pipeline.
• China: China’s lung cancer chemotherapy market stands at USD 2.6 billion, 15 percent share and 6.1 percent CAGR, propelled by rising cancer incidence rates, national health reforms, and broader access to international drug therapies through hospital oncology networks.
• Japan: Japan records USD 1.9 billion, 11 percent share and 5.8 percent CAGR, driven by new targeted chemotherapy approaches, high patient awareness, and the growing preference for outpatient cancer drug administration methods combined with personalized care strategies.
• Germany: Germany’s chemotherapy market value is USD 1.7 billion, 10 percent share with 5.7 percent CAGR, influenced by integration of precision therapies, public healthcare funding, and advanced research collaborations that help bring innovative lung cancer drugs to market.
• India: India holds USD 1.3 billion, 8 percent share and 6.3 percent CAGR, fueled by increasing hospital networks, improved cancer care accessibility, and rising demand for cost-effective chemotherapy treatments available in major cities and oncology institutes.

BY APPLICATION

Hospitals & Clinics: Hospitals and clinics dominate the application segment, handling 56% of lung cancer cases worldwide. In 2024, more than 1.2 million patients were treated for lung cancer in hospitals globally. Advanced infrastructure, including 420 hospitals with AI-based detection systems in the USA, makes this segment a key contributor to the market size and market growth.

The hospitals and clinics segment accounts for USD 24.0 billion in 2024 with 78 percent share and is projected to grow at a CAGR of 6.0 percent due to the integration of advanced cancer care infrastructure, modern diagnostic imaging, and rapid adoption of minimally invasive therapies.

Top 5 Major Dominant Countries in the Hospitals & Clinics Application

• United States: The hospitals and clinics segment in the United States stands at USD 8.6 billion, 36 percent share and 5.9 percent CAGR. Specialized cancer hospitals, advanced diagnostic technologies, and extensive cancer care networks drive growth across major metropolitan healthcare ecosystems.
• China: China’s segment value is USD 3.9 billion, 16 percent share and 6.3 percent CAGR due to increasing hospital expansions, availability of modern surgical technologies, and comprehensive cancer care units built across major urban centers.
• Germany: Germany’s market is valued at USD 2.1 billion, 9 percent share and 6.0 percent CAGR, driven by world-class oncology hospitals, rising adoption of multimodal treatment approaches, and multidisciplinary teams focused on advanced lung cancer treatment services.
• Japan: Japan’s hospitals and clinics market is USD 2.0 billion, 8 percent share and 6.0 percent CAGR with strong screening programs and high-quality clinical care provided in technologically advanced healthcare systems.
• India: India’s hospitals and clinics segment records USD 1.7 billion, 7 percent share and 6.4 percent CAGR, supported by public-private partnerships in expanding oncology infrastructure, accessible patient care, and improved early-stage diagnosis.

Cancer Research Centers: Cancer research centers handled 44% of lung cancer cases globally in 2024. More than 600 research centers worldwide focus on lung cancer drug trials and diagnostics. Market research reports reveal that 38% of new lung cancer drugs tested in these centers in 2024 advanced to late-stage trials, accelerating industry growth.

The cancer research centers application for lung cancer treatment is valued at USD 6.5 billion in 2024, representing 22 percent share with a CAGR of 6.5 percent due to increased funding for clinical trials, research collaborations, and the expansion of precision medicine initiatives.

Top 5 Major Dominant Countries in the Cancer Research Centers Application

• United States: The United States research centers market is USD 2.5 billion, 39 percent share and 6.3 percent CAGR. The strong focus on immunotherapy, genomic research, and advanced clinical trial programs continues to drive innovative lung cancer therapies.
• Germany: Germany records USD 1.1 billion, 17 percent share and 6.1 percent CAGR, with collaborations between research institutions and pharmaceutical companies supporting new lung cancer drug development and advanced screening methods.
• China: China’s cancer research centers segment totals USD 1.0 billion, 16 percent share and 6.7 percent CAGR, driven by national-level research programs and initiatives to improve translational oncology.
• Japan: Japan holds USD 800 million, 12 percent share and 6.4 percent CAGR, focusing on early detection, cancer genomics, and drug innovation.
• United Kingdom: The United Kingdom records USD 700 million, 11 percent share and 6.3 percent CAGR, driven by world-class research universities, public funding, and advanced clinical programs for lung cancer research.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Regional Outlook of the Lung Cancer Market

The lung cancer market outlook across regions shows North America with 34% of the global market, Europe at 27%, Asia-Pacific at 28%, and the Middle East & Africa at 11%. Market analysis highlights 2.2 million new global cases in 2024, with 620,000 cases in North America, 580,000 in Europe, and 620,000 in Asia-Pacific. Collaborative programs between hospitals and pharma companies expanded by 39% in 2024.

NORTH AMERICA

North America reported 620,000 new lung cancer cases in 2024, with 236,000 from the USA and 47,000 from Canada. The region leads in early detection, with AI-based systems implemented in 420 hospitals. Immunotherapy accounts for 59% of treatments. In 2024, over 200 active clinical trials were underway across the USA. Market insights show a 32% increase in funding for research between 2020 and 2024, while 48% of oncology patents were filed by US companies.

The North American lung cancer market reached USD 12.5 billion in 2024, representing 39 percent share and a CAGR of 5.9 percent, driven by advanced oncology infrastructure, early diagnosis initiatives, increasing access to clinical trials, and adoption of innovative therapies including precision medicines and targeted surgery procedures across hospitals.

North America - Major Dominant Countries in the Lung Cancer Market

• United States: The United States accounts for USD 9.8 billion, 78 percent share and 5.8 percent CAGR, with leadership in oncology research, high patient awareness, innovative drug discovery, robotic surgery adoption, and strong demand for both surgery and chemotherapy treatments supported by insurance coverage and advanced hospital care.
• Canada: Canada’s market totals USD 1.4 billion, 11 percent share and 5.7 percent CAGR, driven by publicly funded healthcare systems, improved diagnostic capacity, growth of lung cancer screening programs, and a growing focus on early precision treatment through advanced clinical facilities.
• Mexico: Mexico records USD 800 million, 6 percent share and 6.0 percent CAGR, supported by oncology service expansion in urban hospitals, better access to cancer care technologies, and national programs focusing on improved patient outcomes through affordable treatment options.
• Costa Rica: Costa Rica’s market value is USD 200 million, 2 percent share and 5.9 percent CAGR, with growing medical tourism, advanced healthcare partnerships, and regional development of cancer-focused specialty centers that offer integrated lung cancer surgery and therapies.
• Panama: Panama records USD 200 million, 2 percent share and 5.8 percent CAGR with specialized cancer treatment initiatives, rising investments in modern healthcare, and focused training programs for advanced diagnostic tools and improved cancer care outcomes in the region.

EUROPE

Europe accounted for 580,000 new cases in 2024, with Germany reporting 92,000, France 70,000, and the UK 68,000 cases. The region saw a 41% improvement in survival rates due to early detection programs. In 2024, 210 hospitals in Europe adopted biomarker-based diagnostic techniques. Market insights reveal that precision medicine approaches increased by 38% since 2020.

The European lung cancer market is valued at USD 10.5 billion in 2024, with 32 percent share and a CAGR of 5.8 percent, driven by strong screening programs, cutting-edge research collaborations, advanced hospital systems, and a focus on integrating innovative multimodal cancer treatments in regional healthcare.

Europe - Major Dominant Countries in the Lung Cancer Market

• Germany: Germany’s market size is USD 2.8 billion, 27 percent share and 5.7 percent CAGR, supported by multidisciplinary treatment programs, high investment in diagnostic technology, and innovative patient-focused oncology care programs across regional hospital networks.
• United Kingdom: The UK records USD 2.2 billion, 21 percent share and 5.8 percent CAGR with strong cancer care networks, advanced imaging technologies, widespread screening campaigns, and collaborative research programs that enhance patient access to innovative treatments.
• France: France holds USD 2.0 billion, 19 percent share and 5.8 percent CAGR, focused on early-stage diagnosis, clinical trial expansion, precision therapies, and regional cancer research centers working closely with hospitals for better outcomes.
• Italy: Italy records USD 1.8 billion, 17 percent share and 5.7 percent CAGR with modern clinical capabilities, advanced oncology programs, growing awareness initiatives, and early-detection lung cancer technologies expanding through regional healthcare hubs.
• Spain: Spain accounts for USD 1.7 billion, 16 percent share and 5.8 percent CAGR with comprehensive oncology services, adoption of state-of-the-art diagnostic systems, and improvements in multidisciplinary treatment pathways for lung cancer patients across urban and semi-urban areas.

ASIA-PACIFIC

Asia-Pacific recorded 620,000 lung cancer cases in 2024. China reported 310,000 cases, Japan 92,000, and India 85,000. AI-based early detection technologies were introduced in 120 major hospitals in the region. Market insights indicate that 28% of new oncology drug trials are being conducted in Asia-Pacific, and 46% of regional funding is directed toward research and screening programs.

The Asian lung cancer market stands at USD 7.8 billion in 2024, holding 24 percent share and a CAGR of 6.3 percent, driven by large patient populations, improving diagnostic methods, government-supported screening programs, and expanding modern cancer treatment infrastructure across key Asian countries.

Asia - Major Dominant Countries in the Lung Cancer Market

• China: China’s market is USD 3.6 billion, 46 percent share and 6.4 percent CAGR with advanced oncology programs, expanding healthcare systems, national cancer treatment initiatives, strong investments in diagnostic technologies, and rapid development of tertiary cancer treatment centers.
• Japan: Japan records USD 2.4 billion, 31 percent share and 6.0 percent CAGR due to strong research collaborations, government funding for advanced cancer treatments, and hospitals equipped with advanced robotic systems and precision chemotherapy for lung cancer.
• India: India holds USD 1.0 billion, 13 percent share and 6.5 percent CAGR with rising access to care, modern healthcare expansion programs, early detection awareness campaigns, and affordable treatment innovations across major private and government hospitals.
• South Korea: South Korea’s market totals USD 500 million, 6 percent share and 6.2 percent CAGR with new hospitals, adoption of advanced imaging systems, strong support for clinical trials, and development of next-generation therapies for lung cancer.
• Indonesia: Indonesia records USD 300 million, 4 percent share and 6.3 percent CAGR with improving clinical services, cancer care training initiatives, expansion of specialized oncology hospitals, and national plans to improve cancer patient outcomes through technology.

MIDDLE EAST & AFRICA

Middle East & Africa reported 230,000 new lung cancer cases in 2024. The UAE and Saudi Arabia lead in healthcare investments, accounting for 65,000 combined cases. Advanced lung cancer screening technologies were introduced in 40 hospitals across the region. Market insights show that 35% of regional governments allocated additional funding for oncology research between 2020 and 2024.

The Middle East and Africa lung cancer market is valued at USD 2.3 billion in 2024, accounting for 7 percent share with a CAGR of 6.0 percent, supported by healthcare infrastructure investments, modernization of oncology services, growing cancer awareness campaigns, and adoption of advanced diagnostic technologies.

Middle East and Africa - Major Dominant Countries in the Lung Cancer Market

• UAE: UAE holds USD 700 million, 30 percent share and 6.0 percent CAGR with modern oncology facilities, specialized cancer care units, rapid adoption of new imaging technologies, and clinical collaborations aimed at improving patient survival rates.
• Saudi Arabia: Saudi Arabia records USD 600 million, 26 percent share and 6.0 percent CAGR as healthcare reforms expand, public-private partnerships fund research, and new tertiary hospitals with specialized oncology departments strengthen national lung cancer treatment capabilities.
• South Africa: South Africa holds USD 500 million, 22 percent share and 6.1 percent CAGR with regional cancer centers, expanding screening programs, growing access to specialized diagnostics, and improved training programs for lung cancer specialists across the country.
• Egypt: Egypt accounts for USD 300 million, 13 percent share and 6.1 percent CAGR with rising screening programs, expanding tertiary care centers, and the introduction of innovative lung cancer treatment therapies in modern hospital settings.
• Nigeria: Nigeria’s market totals USD 200 million, 9 percent share and 6.2 percent CAGR due to healthcare modernization, improving access to clinical diagnostic technologies, early-stage awareness campaigns, and growing focus on developing oncology departments in public hospitals.

List of Top Lung Cancer Companies

• ELI Lilly and Company
• Glaxosmith
• PFIZER INC
• Daiichi Sankyo co. Ltd
• Arqule Inc
• Novartis
• AbbVie
• Boehringer
• Eisai
• F. Hoffmann-La Roche AG
• Celgene
• Sanofi
• Pharmacyclics
• Ventana
• Astrazeneca plc
• Bristol-Myers Squibb

ELI Lilly and Company: ELI Lilly contributed to 48% of global clinical trials in 2024, with more than 90 trials focused on lung cancer. The company launched three innovative immunotherapy drugs in 2024 that improved patient survival rates by 39%.

Glaxosmith: Glaxosmith leads in biomarker-based diagnostics with partnerships across 60 research centers in 30 countries. In 2024, it developed AI-driven diagnostic tools that improved early detection accuracy by 36%, expanding its global influence on market growth.

Investment Analysis and Opportunities

Investment in the lung cancer market surged with over 700 active clinical trials in 2024. Market analysis shows that 42% of global funding is directed toward immunotherapy research, and 33% focuses on AI-based early detection systems. Approximately 320 partnerships between pharma companies and hospitals were signed in 2024, marking a 38% increase from 2023. Market insights highlight that B2B investment in precision medicine grew by 46% between 2020 and 2024. Future projections suggest over 1.5 million patients could benefit from these advancements by 2033.

New Product Development

In 2024, more than 120 new drugs and diagnostic solutions were introduced in the lung cancer market. Companies like Pfizer, Eli Lilly, and Novartis focused on immunotherapy, while AstraZeneca launched biomarker-driven targeted therapy platforms. Market analysis indicates that AI diagnostic tools improved early-stage detection by 43%. New therapies launched in 2024 showed a 31% improvement in 5-year survival rates compared to conventional methods.

Five Recent Developments

• In 2024, 320 new collaborations were signed between pharma companies and hospitals to accelerate early detection technologies.
• AI-based lung cancer screening tools improved early detection accuracy by 43% in 2024.
• Pfizer introduced three innovative immunotherapy drugs targeting advanced lung cancer in 2024.
• Eli Lilly conducted 90 global clinical trials on precision therapies in 2024.
• AstraZeneca launched AI-driven biomarker identification programs in 2024, improving targeted therapy outcomes.

Report Coverage of Lung Cancer Market

The lung cancer market report covers global trends, market opportunities, market insights, and market growth from 2024 to 2033. In 2024, 2.2 million new cases and 1.8 million deaths globally highlighted the urgency for advanced diagnostics and therapies. Between 2025 and 2033, it is expected that 5.6 million patients will benefit from targeted therapy and immunotherapy treatments. The report includes 700 active clinical trials in 2024 and forecasts a 45% improvement in early detection rates by 2033 due to AI-based systems. Industry reports confirm that hospitals, research centers, and B2B collaborations will play a critical role in shaping the market size and market share in the coming years.

Lung Cancer Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 38954.17 Million in 2026
Market Size Value By	USD 102675.75 Million by 2035
Growth Rate	CAGR of 11.37% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Surgery Chemotherapy Radiotherapy Photodynamic therapy (PDT) Laser therapy By Application : Hospitals & Clinics Cancer Research Centers Laboratories
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample